重组人血管内皮抑素联合化疗治疗老年晚期非小细胞癌的近期疗效及对肿瘤标志物的影响

摘要

Objective:To investigate the clinical efficacy of recombinant human endostatin (rh-ES) combined with first-line chemotherapy in the treatment of elderly patients with advanced non-small cell cancer (NSCLC) and its effect on tumor markers.Methods:A retrospective analysis of 110 cases of elderly patients with advanced NSCLC were retrospectively analyzed,divided into A group (combined group,58 cases) and B group (control group,52 cases),group B with 4 ～6 cycles of DP or GP chemotherapy,A group in B group based on the use of rh-ES injection,chemotherapy patients the two group after the 30d clinical curative effect and safety of tumor marker cancer antigen (CA125),carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA21-1) and vascular endothelial growth factor (VEGF) changes.Results:The KPS score and the incidence of cardiac dysfunction in A group were significantly higher than those in group B (P ＜ 0.05).VEGF,CEA,CA12s and CYFRA21-1 were significantly lower in group A than in group B (P ＜ 0.05).There was no significant difference between the two groups in tumor control rate,clinical benefit rate and the incidence of drug toxicity in the two groups (P ＞0.05).Conclusion:The combination chemotherapy with rs-ES can improve the short-term efficacy and quality of life,reduce the tumor load,but should pay attention to the cardiovascular toxicity of rh-ES in elderly patients with advanced NSCLC.%目的:探讨重组人血管内皮抑素(rh-ES)联合一线化疗方案治疗老年晚期非小细胞癌(NSCLC)的临床疗效及对肿瘤标志物的影响.方法:回顾性分析110例老年晚期NSCLC患者病历资料,分为A组(联合组,58例)和B组(对照组,52例),B组采用4～6周期DP或GP化疗方案,A组在B组基础上加用rh-ES注射液,比较两组患者化疗结束后30d临床疗效与安全性,肿瘤标志物癌癌抗原(CA125)、胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)及血管内皮生长因子(VEGF)变化.结果:A组化疗后KPS评分、心功能损害发生率明显高于B组(P＜0.05).A组化疗结束后VEGF、CEA、CA125、CYFRA21-1均显著低于B组(P＜0.05).两组肿瘤控制率、临床获益率、化疗期间两组药物毒性反应及发生率的差异均无统计学意义(P＞0.05).结论:一线化疗方案治疗老年晚期NSCLC基础上联合应用rs-ES注射液能辅助提高近期疗效与生活质量,降低肿瘤载荷,但应注意rh-ES的心血管毒性.